Eli Lilly Wins First Approval for Foundayo Weight-Loss Drug in UK, Becomes Second GLP-1 Pill in Europe
Eli Lilly has won regulatory approval to sell its weight-loss drug Foundayo in the U.K., marking the company's first authorization outside the U.S. The approval makes Foundayo only the second GLP-1 weight-loss pill available in the European market, allowing it to directly compete with Novo Nordisk's
NVO+2.19%
GateNews·08-11 12:01
